Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome.
about
The metabolic syndromeImmunomodulation and anti-inflammatory effects of garlic compounds.Elevated Urinary T Helper 1 Chemokine Levels in Newly Diagnosed Hypertensive Obese ChildrenEight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and womenLong-term effects intensive medical therapy on the development and progression of subclinical atherosclerosis and the metabolic syndrome in Chinese patients with type 2 diabetes mellitus.Garlic: nature's protection against physiological threats.AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.Garlic and cardioprotection: insights into the molecular mechanisms.Combating Combination of Hypertension and Diabetes in Different Rat ModelsCRTC3 polymorphisms were associated with the plasma level of total cholesterol and the risks of overweight and hypertriglyceridemia in a Chinese Han population.Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats.Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.The Combined Effects of Exercise, Diet, and a Multi-Ingredient Dietary Supplement on Body Composition and Adipokine Changes in Overweight Adults.
P2860
Q33569142-F0AFE602-4C72-4FDA-9147-1A33D4E972CEQ35563390-93FC144C-F843-44C2-A5B9-16ED2A97F241Q36367765-2DAEC63D-C568-4AFB-9B0F-07DEBD961FB6Q36805313-41176AAB-23F0-4550-A2AE-C67349C2C73FQ37432907-9D4CB300-198B-4364-9963-27877A786850Q37502883-324B6C35-6680-4FF5-AA92-8CCCE680EC9EQ37510211-608A7F4F-F621-4713-BF1B-12FB942AF6C1Q38112809-BC9B11DA-FF67-4EC7-BD53-4EEAA1B3732EQ38974232-6F57141D-AFF4-4212-9889-8C5F6C224587Q39330292-363D8E74-0D7A-4A66-A33C-843F0A89DB05Q39474625-B5ABEACD-6ECA-4860-9234-BF9DFF2622E1Q41630778-A2BCAABD-EE03-4830-9321-F7C3D62EC880Q43297018-25359E3D-6F59-4267-9CA5-387BDE9304A8Q50018586-3DD2B314-7A19-4A6F-B801-B65A4BB08F15Q50124112-FDD637E0-8D84-4BE2-A9B0-1C3A0C2D8A51
P2860
Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@ast
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@en
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@nl
type
label
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@ast
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@en
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@nl
prefLabel
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@ast
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@en
Therapeutic actions of allylme ...... t model of metabolic syndrome.
@nl
P2093
P2860
P1476
Therapeutic actions of allylme ...... at model of metabolic syndrome
@en
P2093
David Mirelman
Janean L Johnson
Richard J Koletsky
Talma Rosenthal
P2860
P304
P356
10.1016/J.AMJHYPER.2007.02.015
P577
2007-08-01T00:00:00Z